ALDH1A1 and neoplasm: As shown in Fig. 5f, compared to Bevacizumab group, the percentage of ALDH1+ cells decreased 41.8% in MDA-MB-231 tumor tissues and 67.3% in MDA-MB-468 tumor tissues when treated by Bevacizumab + SHH002-hu1 (MDA-MB-231: *p < 0.05, MDA-MB-468: **p < 0.01).